

FORM 51 – 102F3
MATERIAL CHANGE REPORT

1. Name and Address of Company

bioMmune Technologies Inc.
1780 – 400 Burrard Street
Vancouver, BC V6C 3A6

2. Date of Material Change

December 8, 2015

3. News Release

News release dated December 9, 2015 was disseminated through Marketwired and was filed via SEDAR on December 9, 2015.

4. Summary of the Material Change

BioMmune Technologies Inc. Announces Appointment of Directors.

5. Full Description of the Material Change

bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V:IMU), a company focused on harnessing the body’s immune system to fight cancer and autoimmune diseases, is pleased to announce that Patrick W. Gray, PhD. and Reinhard Gabathuler PhD have been elected as directors of the Company at its Annual and Special Meeting held on December 8, 2015 in Vancouver, B.C.

Dr. Gray has spent 35 years in the biotechnology industry, focusing on drug discovery for critical diseases. He has a passion for working in small companies with aggressive timelines---Genentech, ICOS, MacroGenics, Nura and Accelerator were all less than 60 employees when he joined. Dr. Gray’s career accomplishments include the first cloning and characterization of Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), Macrophage Derived Chemokine, and PI3K p110-delta. These discoveries led to numerous clinical trials, several approved human pharmaceuticals, and characterization of targets for therapeutic monoclonal antibodies and small molecules. In addition to his scientific accomplishments, Dr. Gray previously held senior scientific management positions, including Vice President, Chief Scientific Officer, and CEO. Dr. Gray received his PhD. in chemistry from the University of Colorado and his BS in biology from the University of Oregon. He is currently an affiliate professor at the University of Washington. Dr. Gray is also Chief Scientific Officer of the Company.

Dr Gabathuler obtained his PhD in Plant Biochemistry at the Université de Lausanne, Switzerland, in 1982, and completed postdoctoral studies at the University of Washington, Seattle. Over the years, he has held various research positions at the Swiss Institute for Experimental Cancer Research, Lausanne; the Ludwig Institute for Cancer

Research at the Karolinska Institutet, Stockholm, Sweden; and the Biotechnology Laboratory of the University of British Columbia, Vancouver, Canada. His research on new vector for delivery of therapeutics to the brain led to the creation of Synapse Technologies Inc., where he became the Vice President of Research. The company was later acquired by BioMarin Pharmaceutical Inc., where Dr Gabathuler assumed the position of Vice President of Brain Research. Dr Gabathuler joined AngioChem Inc. in 2004 as its Chief Scientific Officer and has applied his extensive knowledge in biochemistry, cell biology, and immunology to directing the R&D programs, advancing the company's product ANG1005 to IND application and into the clinic. He is now involved as Chief Scientist at biOasis Technologies Inc. in the development of new peptide vector, Transcend for delivery of molecular cargo through the blood brain barrier. Dr. Gabathuler is also President and CEO of bioMmune.

The Company is also pleased to announce that Karoly Nikolich PhD has been appointed as Chairman of the Board of Directors.

Dr. Nikolich is a renowned biotechnology expert with an extensive track record within this industry. Highlights include: former head of the Neuroscience Program at Genentech Inc.; Adjunct Professor, Neuroscience, USC, Los Angeles, CA; Vice President, Research, Lynx Therapeutics, Inc. Hayward, CA and Director (Supervisory Board) BASF-LYNX Bioscience AG, Heidelberg; former CEO, Amnestix, Inc., and Neurofluidics, Inc., Burlingame, CA; Executive Director, Neuroscience Institute at Stanford (NIS), Stanford University Medical School; Founder, Chief Executive Officer, and Director (Board member) AGY Therapeutics, Inc., South San Francisco, CA; and currently Dr. Nikolich is Founder and President of Circuit Therapeutics, Inc., and a consulting Professor at Stanford University Medical School. Along with an extensive professional history, Dr. Nikolich has been an author on over 120 scientific and review publications.

The Company also would like to announce that Robin Hutchison and J. Michael Hutchison have stepped down as directors of the Company. The Board of Directors would like to thank them for their contributions and wish them well in their future endeavors.

Following the Annual and Special Meeting held on December 8, 2015, members of the Board of Directors are:

Dr. Reinhard Gabathuler, President and CEO
Dr. Patrick Gray, Chief Scientific Officer
Dr. Karoly Nikolich, Chairman of the Board
Dr. Terry Pearson
Jens Biertumpel

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Dr. Reinhard Gabathuler, President
Phone: (514) 963-6177

9. Date of Report

December 18, 2015